Vertex Drug Promising in Hepatitis C Patients With HIV
March 7, 2011
Substantially more HIV/hepatitis C virus co-infected patients taking the investigational HCV drug telaprevir achieved a rapid viral response (RVR) than those taking standard therapy alone, researchers reported at the 18th Conference on Retroviruses and Opportunistic Infections in Boston. RVR, defined as undetectable HCV after four weeks of treatment, can be an early indicator of eventually attaining a sustained viral response (SVR).
In previous trials, telaprevir has improved rates of SVR when used in combination with pegylated interferon and ribavirin. Vertex Pharmaceuticals Inc.'s drug is awaiting approval by the Food and Drug Administration.
03.02.2011; Bill Berkrot
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)